PureTech plumbs the brain
Why PureTech is targeting brain lymphatics to treat neurodegeneration
PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by Jonathan Kipnis at the University of Virginia.
The company licensed the IP from UVA and will collaborate with the academic group to develop modulators of brain lymphatic vessels. Terms of the deal are undisclosed.
The findings add a mechanism to how β-amyloid and other proteins are cleared from the brain, which also occurs via transfer across the blood-brain barrier to the bloodstream or enzymatic breakdown inside the brain.
In 2015, Kipnis overturned a long-standing dogma in neuroscience by showing that the meningeal membranes around the brain contain a network of lymphatic vessels. Before then, the brain was thought to be the only organ lacking the vessels. Results were published in Nature.
The outstanding questions have been whether the brain’s lymph vessels drain macromolecules from its interstitial fluid, and if so, whether their dysfunction might contribute to neurodegenerative disorders by causing toxic molecules to build up.
“The view has been Alzheimer’s is a disease of protein homeostasis. The problem could be a drainage issue rather than some intrinsic parenchyma problem.”
In a Nature paper published July 25, Kipnis’ group shows both